TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $18

Benzinga · 3d ago
TD Cowen analyst Yaron Werber maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $49 to $18.